Hypnogen

Zolpidem tartrate, the active ingredient in Hypnogen, is a Imidazopyridine (non‑benzodiazepine) sedative‑hypnotic presented as an oral tablet for oral use. It is indicated for the short‑term treatment of insomnia, particularly difficulty falling asleep, in adult patients.

GNH USA supplies Hypnogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem tartrate acts on the central nervous system to facilitate sleep onset in patients with insomnia.

- Insomnia (difficulty falling asleep): helps initiate sleep and improve sleep latency. - Short‑term insomnia: provides rapid sleep onset for brief treatment courses.

Zolpidem tartrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: sensation of light‑headedness or imbalance. - Headache: mild to moderate head pain. - Nausea: upset stomach or feeling of queasiness. - Dry mouth: reduced salivation. - Amnesia: difficulty recalling events after waking.

Serious or Rare Side Effects: - Complex sleep behaviors: sleepwalking, sleep‑driving, or other activities while not fully awake. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Depression or suicidal thoughts: mood changes requiring immediate medical attention. - Severe rash or Stevens‑Johnson syndrome: extensive skin involvement. - Respiratory depression: slowed breathing, especially when combined with other depressants. - Hallucinations or psychotic symptoms: visual or auditory disturbances.

Before using Hypnogen, consider the following safety measures.

- Avoid alcohol: concurrent use may intensify sedation and respiratory depression. - Use caution in hepatic impairment: reduced metabolism can increase drug exposure. - Do not operate machinery: impaired alertness can affect driving or operating equipment. - Pregnancy: consult a healthcare professional before use, as safety data are limited. - Elderly patients: increased sensitivity may require lower doses. - Store below 25°C: keep in the original pack, protect from moisture.

Zolpidem tartrate can interact with several medicines, altering its effects or safety profile.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Other CNS depressants (e.g., benzodiazepines, opioids): heightened sedation and respiratory risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced efficacy. - Antihistamines (e.g., diphenhydramine): may enhance drowsiness. - Certain antidepressants (e.g., fluoxetine): possible increased sedation.